The newest treatment being used for macular degeneration involves use of drugs called anti-vascular endothelial growth factor (anti-VEGF) medications. These drugs help stop new CNV from growing by blocking the effects of a growth factor these blood vessels need to thrive. Anti-VEGF medications are injected directly into your eye. Some anti-VEGF agents that have been approved for use or are currently being investigated for treating macular degeneration include:
Ranibizumab (Lucentis) is an anti-VEGF drug used to treat wet macular degeneration. It also impedes new growth of abnormal blood vessels and helps dry up leaking vessels. However, ranibizumab may be able to reverse some of the effects of macular degeneration, not just prevent further vision loss.
LUCENTIS® (ranibizumab injection) is a prescription medicine for the treatment of patients with wet age-related macular degeneration (AMD).
LUCENTIS is a breakthrough treatment for wet AMD that can do more than just help you maintain your vision. With LUCENTIS, people with wet AMD may see their vision improve or keep the vision they have.
LUCENTIS is an FDA-approved treatment specifically developed for the treatment of wet AMD.
Of patients in key clinical studies taking LUCENTIS monthly...
Up to 40% of patients had a significant improvement of at least 3 more lines (15 letters) on the eye chart
70% of patients could see at least 1 more letter on the eye chart
95% of patients had their eyesight stay the same (lost fewer than 15 letters or 3 lines)
Up to 40% of patients achieved vision of 20/40 or better
And did you know that LUCENTIS...
Was specifically developed for use in the eye, and is NICE and FDA approved for the treatment of wet AMD? It is also approved for the treatment of diabetic maculopathy and retinal vein occlusion.
Eylea® (VEGF-trap, Aflibercept) is a new anti-VEGF agent that is NICE and FDA approved for wet ARMD treatment with an innovative mechanism of action that 'traps' VEGF-A and PlGF. EYLEA helps gain and maintain visual acuity for wet AMD patients in the first year of treatment and beyond. It has the advantages of fewer injections being required and fewer monitoring visits to clinic as well. It is also licensed for treatment of retinal vein occlusion.